Myriad Applauds the U.S. Preventive Services Task Force Recommendation on BRCA-Related Cancer Prevention August 22, 2019 Myriad Applauds the U.S. Preventive Services Task Force Recommendation on BRCA-Related Cancer Prevention More Women May Benefit from Hereditary Cancer Risk Ass... Continue Reading
Myriad Will Seek FDA Approval of BRACAnalysis CDx® As a Companion Diagnostic for Lynparza® (olaparib) In Men with Metastatic Castrate-Resistant Prostate Cancer August 7, 2019 Myriad Will Seek FDA Approval of BRACAnalysis CDx® As a Companion Diagnostic for Lynparza® (olaparib) In Men with Metastatic Castrate-Resistant Prostate Cance... Continue Reading
Prolaris® Test Accurately Predicts Risk of Metastasis in Men Diagnosed with Localized Prostate Cancer June 27, 2019 Prolaris® Test Accurately Predicts Risk of Metastasis in Men Diagnosed with Localized Prostate Cancer Validation Study Shows Prolaris Test Identifies Men Who M... Continue Reading
BRACAnalysis CDx® Approved by U.S. Food and Drug Administration as Companion Diagnostic for AstraZeneca’s Lynparza® (olaparib) in Patients with Advanced-Stage, BRCA-Mutated Ovarian Cancer June 24, 2019 BRACAnalysis CDx® Approved by U.S. Food and Drug Administration as Companion Diagnostic for AstraZeneca’s Lynparza® (olaparib) in Patients with Advanced-Sta... Continue Reading
Myriad Genetics Announces New Results from Two Large Studies of Its myRisk® Hereditary Cancer Test at American Society of Clinical Oncology June 3, 2019 Myriad Genetics Announces New Results from Two Large Studies of Its myRisk® Hereditary Cancer Test at American Society of Clinical Oncology SALT LAKE CITY, Jun... Continue Reading
BRACAnalysis CDx® Companion Diagnostic Test Identifies Patients with Metastatic Pancreatic Cancer Who Benefited from Treatment with Lynparza® (olaparib) June 2, 2019 BRACAnalysis CDx® Companion Diagnostic Test Identifies Patients with Metastatic Pancreatic Cancer Who Benefited from Treatment with Lynparza® (olaparib) NCCN ... Continue Reading
New Publication Shows the EndoPredict® Test Identifies Women with Early-Stage Breast Cancer Who Can Forgo Extended Endocrine Therapy May 9, 2019 New Publication Shows the EndoPredict® Test Identifies Women with Early-Stage Breast Cancer Who Can Forgo Extended Endocrine Therapy New Study Finds Approximat... Continue Reading
EndoPredict® Predicts the Chemotherapy Benefit in Women with Early ER-positive, HER2-negative Breast Cancer April 30, 2019 [vc_row][vc_column][vc_column_text el_class=" text-corporate"] EndoPredict® Predicts the Chemotherapy Benefit in Women with Early ER-positive, HER2-negative Br... Continue Reading
Myriad Genetics Submits First Module of the Premarket Approval Application to FDA for the myChoice® HRD CDx Test April 9, 2019 Myriad Genetics Submits First Module of the Premarket Approval Application to FDA for the myChoice® HRD CDx Test myChoice HRD Is Intended to Identify Patients ... Continue Reading
Myriad, AstraZeneca and Merck Expand Companion Diagnostic Partnership April 4, 2019 Myriad, AstraZeneca and Merck Expand Companion Diagnostic Partnership BRACAnalysis CDx® Test Will Be Used to Identify Germline BRCA Mutations in Men with Metas... Continue Reading